Biomarkers vs Machines: The Race to Predict Acute Kidney Injury
Clinical Chemistry · 03.06.2024 · 70 (6) · 805-819
DOI: 10.1093/clinchem/hvad217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Chemistry, online erschienen am 01.02.2024. Verfasst von Lama Ghazi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294, United States. Hauptthemen laut MEDLINE: Acute Kidney Injury, Biomarkers. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 80 Literaturangaben.
Abstract (Originalsprache)
Background Acute kidney injury (AKI) is a serious complication affecting up to 15% of hospitalized patients. Early diagnosis is critical to prevent irreversible kidney damage that could otherwise lead to significant morbidity and mortality. However, AKI is a clinically silent syndrome, and current detection primarily relies on measuring a rise in serum creatinine, an imperfect marker that can be slow to react to developing AKI. Over the past decade, new innovations have emerged in the form of biomarkers and artificial intelligence tools to aid in the early diagnosis and prediction of imminent AKI. Content This review summarizes and critically evaluates the latest developments in AKI detection and prediction by emerging biomarkers and artificial intelligence. Main guidelines and studies discussed herein include those evaluating clinical utilitiy of alternate filtration markers such as cystatin C and structural injury markers such as neutrophil gelatinase-associated lipocalin and tissue inhibitor of metalloprotease 2 with insulin-like growth factor binding protein 7 and machine learning algorithms for the detection and prediction of AKI in adult and pediatric populations. Recommendations for clinical practices considering the adoption of these new tools are also provided. Summary The race to detect AKI is heating up. Regulatory approval of select biomarkers for clinical use and the emergence of machine learning algorithms that can predict imminent AKI with high accuracy are all promising developments. But the race is far from being won. Future research focusing on clinical outcome studies that demonstrate the utility and validity of implementing these new tools into clinical practice is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294, United States.
- Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
- Renal Division, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
- Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT 06510, United States.
- Computational Biology and Bioinformatics, Yale University, New Haven, CT 06510, United States.
ORCID-Profile: Lama Ghazi, Joe M El-Khoury
Zitieren
APA
Ghazi, L., Farhat, K., Hoenig, M. P., Durant, T. J. S., & El-Khoury, J. M. (2024). Biomarkers vs Machines: The Race to Predict Acute Kidney Injury. Clinical Chemistry, 70(6), 805-819. https://doi.org/10.1093/clinchem/hvad217
Vancouver
Ghazi L, Farhat K, Hoenig MP, Durant TJS, El-Khoury JM. Biomarkers vs Machines: The Race to Predict Acute Kidney Injury. Clinical Chemistry. 2024;70(6):805-819. doi:10.1093/clinchem/hvad217
BibTeX
@article{Ghazi2024,
author = {Ghazi, Lama and Farhat, Kassem and Hoenig, Melanie P and Durant, Thomas J S and El-Khoury, Joe M},
title = {Biomarkers vs Machines: The Race to Predict Acute Kidney Injury},
journal = {Clinical Chemistry},
year = {2024},
volume = {70},
number = {6},
pages = {805--819},
doi = {10.1093/clinchem/hvad217}
}
EUVIMED